The feasibility of transcatheter arterial chemoembolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. 30 cases receiving TACE were denoted the TACE group, another 30 cases receiving TACE combined with an intratumoral multi-point injection of cisplatin were denoted the TACE/cisplatin group. Cases with partial remission/complete remission (PR/CR) were analyzed using 2 tests; alpha fetoprotein (AFP), aspartate amino transferase (AST), total bilirubin (TBIL), erythrocyte, and platelet levels were detected and the differences between two groups were analyzed using the Student’s t-test; cases with complications, including intrahepatic metastasis (IM), upper gastrointestinal bleeding (UGB), and liver failure were also counted. The correlation of clinical parameters with PR/CR was analyzed using multifactorial correlation analysis. Cases with PR/CR in the TACE/cisplatin group were significantly more than in TACE group, accompanied by significant declination in FAP. There were no significant differences of AST, ALT, TBIL, blood urea nitrogen (BUN), white blood cells (WBC), red blood cells (RBC), and platelets (PLT) between two groups; 3 cases with IM, one case with UGB and one case with LF were found in the TACE group, but only 1 case with IM was found in the TACE/cisplatin group. In addition, tumor stage was correlated with PR/CR. We concluded that TACE combined with intratumoral injection of cisplatin was more effective than TACE, and with fewer complications and side effects.
patients with stage III hepatocellular carcinoma, Am. J. Clin. Oncol., 2003, 26, e92–99  Sahara S., Kawai N., Sato M., Tanaka T., Ikoma A., Nakata K., et al., Prospective Evaluation of TranscatheterArterialChemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma, Cardiovasc. Intervent. Radiol., 2012, doi: 10.1007/s00270-012-0352-x  Chen S., Li B., Xie H., Xu L., Niu G., Fan K., et al., Phase I clinical trial of targeted therapy
Brain metastasis (BM) has been universally recognized as a poor prognostic factor in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown efficacy in treating BM with an EGFR mutation. This paper reports a case of BM patient with EGFR-mutated NSCLC. According to the findings, a complete remission (CR) of the BM was achieved by icotinib treatment without conducting a radiotherapy, which was followed by a resection of the primary lung cancer lesion and lymph nodes. After one-year follow-up, the disease progressed to liver metastasis and liver lesion biopsy showed a T790M mutation. The patient responded well to the combination treatment of AZD9291 and icotinib after the failure of transcatheter arterial chemoembolization (TACE). This case report suggests that icotinib has a sustainable anticancer response to BM and the combination with icotinib and AZD9291 is effective for liver metastasis with T790M.
Background: CD4+CD25+ forkhead box P3 (FOXP3)+ regulatory T cells (Tregs) accumulate in malignant tumors and negatively regulate antitumor immunity. However, the clinical significance of Tregs in HCC remains unclear. To determine the prognostic value of Tregs, we conducted a retrospective study on 264 patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) who underwent transcatheter arterial chemoembolization (TACE).
Methods: We measured the proportion of peripheral blood Tregs in 105 healthy donors and 264 HCC patients (stage B) prior to and following TACE between 2005 and 2007. All HCC patients were followed up until December 2012. The correlations between the proportion of Tregs and clinicopathologic factors were analyzed, and long-term survival rate after TACE according to the percentage of Tregs was assessed by univariate and multivariate analyses.
Results: The 1-, 2-, 3-, 4- and 5-year cumulative survival rates were 62.1%, 32.6%, 16.5%, 10.4% and 6.9%, respectively, and the median survival time was 19.0 months. The cumulative survival rate was significantly lower in patients with higher levels of peripheral blood Treg cells compared to those with lower Treg levels (p<0.001). Furthermore, we found that both pre- and post-TACE peripheral blood Treg levels showed significant negative association with overall survival time (p<0.001).
Conclusions: Elevated peripheral blood CD4+CD25+FOXP3+Treg levels are an independent predictive factor of poor survival after TACE for HCC (stage B) patients. These results suggest that targeting Tregs may improve patient outcomes, and provide a strong rationale for testing these approaches in future immunotherapy-based clinical trials.
, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768. 19. Leelawat K, Laisupasin P, Kiatdilokrut A, Pongtongpool T, Narong S, Samkhumphim N, Ket-Horm S. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheterarterialchemoembolization (TACE). J Med Assoc Thai. 2008;91:1539-1543. 20. Chen C, Wang J, Liu R, Qian S. RNA
.1016/j.jvir.2013.10.017 24295569 Dekervel J van Malenstein H Vandecaveye V Nevens F van Pelt J Heye S Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up J Vasc Interv Radiol 2014 25 248 248 10.1016/j.jvir.2013.10.017 14 Huppert P, Wenzel T, Wietholtz H. Transcatheterarterialchemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol 2014; 37 : 154
Introduction Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. The HCC incidence in the USA has tripled since the early 1980s [1, 2]. Although various therapeutic strategies are available to treat HCC including surgical resection, ablation, liver transplantation, transcatheterarterialchemoembolization (TACE), and the multikinase inhibitor sorafenib, the 5-year survival of HCC is still low, especially when the disease is diagnosed at advanced stages . Therefore, there is an urgent need to develop more effective diagnostic
29 HCC patients included in the transplant waiting list for OLT (with Milan Criteria) were evaluated. Isolation and count of
CTCs were performed by IsoFlux™ system (Fluxion) and fluorescence microscopy. Spearman Rho test was used to evaluate
the relation between CTCs and time on the transplant list, time from diagnosis, number of tumors, number of transcatheterarterialchemoembolization (TACE) and Standard uptake value. To assess the role of CTCs in 21 patients post-transplant
and their relation with vascular invasion, Wilcoxon and Mann-Whitney tests